Wearing-off symptoms during standard and extended natalizumab dosing intervals : Experiences from the COVID-19 pandemic
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved..
Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis, but many treated patients report subjective wearing-off symptoms at the end of the 4-week interval between infusions. Extended interval dosing (EID) is a promising strategy to mitigate the risk of natalizumab-associated progressive multifocal leukoencephalopathy, but it is unknown whether EID affects wearing-off symptoms. In this observational study, we evaluated if prevalence or intensity of wearing-off symptoms changed when natalizumab dosing intervals were extended from 4 to 6 weeks in 30 treated patients during the outbreak of COVID-19 in Norway. New or increased wearing-off symptoms during EID were reported by 50%. Symptom increase was more frequent among patients with pre-existing wearing-off symptoms during standard dosing compared to patients without such pre-existing symptoms [p = 0.0005]. Our observations support the need to study the effect of EID on wearing-off symptoms in randomized controlled trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:429 |
|---|---|
| Enthalten in: |
Journal of the neurological sciences - 429(2021) vom: 15. Okt., Seite 117622 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bringeland, Gerd Haga [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Extended interval dosing |
|---|
| Anmerkungen: |
Date Completed 29.09.2021 Date Revised 17.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jns.2021.117622 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330167995 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330167995 | ||
| 003 | DE-627 | ||
| 005 | 20231225210715.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jns.2021.117622 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1100.xml |
| 035 | |a (DE-627)NLM330167995 | ||
| 035 | |a (NLM)34474301 | ||
| 035 | |a (PII)S0022-510X(21)00316-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bringeland, Gerd Haga |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Wearing-off symptoms during standard and extended natalizumab dosing intervals |b Experiences from the COVID-19 pandemic |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2021 | ||
| 500 | |a Date Revised 17.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis, but many treated patients report subjective wearing-off symptoms at the end of the 4-week interval between infusions. Extended interval dosing (EID) is a promising strategy to mitigate the risk of natalizumab-associated progressive multifocal leukoencephalopathy, but it is unknown whether EID affects wearing-off symptoms. In this observational study, we evaluated if prevalence or intensity of wearing-off symptoms changed when natalizumab dosing intervals were extended from 4 to 6 weeks in 30 treated patients during the outbreak of COVID-19 in Norway. New or increased wearing-off symptoms during EID were reported by 50%. Symptom increase was more frequent among patients with pre-existing wearing-off symptoms during standard dosing compared to patients without such pre-existing symptoms [p = 0.0005]. Our observations support the need to study the effect of EID on wearing-off symptoms in randomized controlled trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Extended interval dosing | |
| 650 | 4 | |a Individualized medicine | |
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 4 | |a Natalizumab | |
| 650 | 4 | |a Receptor occupancy | |
| 650 | 4 | |a Wearing-off | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Natalizumab |2 NLM | |
| 700 | 1 | |a Blaser, Nello |e verfasserin |4 aut | |
| 700 | 1 | |a Myhr, Kjell-Morten |e verfasserin |4 aut | |
| 700 | 1 | |a Vedeler, Christian Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Gavasso, Sonia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the neurological sciences |d 1964 |g 429(2021) vom: 15. Okt., Seite 117622 |w (DE-627)NLM000061956 |x 1878-5883 |7 nnns |
| 773 | 1 | 8 | |g volume:429 |g year:2021 |g day:15 |g month:10 |g pages:117622 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jns.2021.117622 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 429 |j 2021 |b 15 |c 10 |h 117622 | ||